Karolinska Development (B) Aktie

0,0617 EUR -0,0641 EUR -50,95 %

08.04.2025

FSE

0,8500 SEK +0,0010 SEK +0,12 %

08.04.2025

STO

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.20,82 Mio. EUR

Div. Rendite0,00%

WKNA0M84G

ISINSE0002190926

SymbolKDEVF

Karolinska Development (B) Aktien News

Sortieren:Datum Meistgelesen

22.03.24GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

22.03.24GlobeNewswireKarolinska Development Annual Report 2023 published

14.03.24GlobeNewswireKarolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

14.03.24GlobeNewswireKarolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

06.03.24GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD

16.02.24GlobeNewswireYear-end Report - January-December 2023

17.01.24GlobeNewswireKarolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round

09.01.24GlobeNewswireKarolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

06.12.23GlobeNewswireKarolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates

04.12.23GlobeNewswireKarolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration

28.11.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis

17.11.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone

17.11.23GlobeNewswireInterim Report - January-September 2023

08.11.23GlobeNewswireKarolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin

02.10.23GlobeNewswireKarolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047

28.09.23GlobeNewswireKarolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047

27.09.23GlobeNewswireKarolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company

19.09.23GlobeNewswireKarolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication

25.08.23GlobeNewswireInterim Report - January-June 2023

05.07.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease

07.06.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation

16.05.23GlobeNewswireKarolinska Development’s Annual General Meeting 2023

12.05.23GlobeNewswireKarolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia

28.04.23GlobeNewswireInterim Report - January-March 2023

17.04.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis

13.04.23GlobeNewswireKarolinska Development’s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01

11.04.23GlobeNewswireNotice of Annual General Meeting in Karolinska Development AB (publ)

28.03.23GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone

24.03.23GlobeNewswireKarolinska Development Annual Report 2022 published

14.03.23GlobeNewswireKarolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01

13.03.23GlobeNewswireKarolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection

28.02.23GlobeNewswireKarolinska Development’s portfolio company SVF Vaccines initiates clinical phase 1 study of its universal Covid-19 vaccine

28.02.23GlobeNewswireKarolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million

21.02.23GlobeNewswireKarolinska Development’s portfolio company Modus Therapeutics presents positive results from a clinical trial of sevuparin

17.02.23GlobeNewswireYear-end Report - January-December 2022

14.02.23GlobeNewswireKarolinska Development’s portfolio company Dilafor reports maintained effect in the extension study of tafoxiparin

18.11.22GlobeNewswireInterim Report - January-September 2022

19.08.22GlobeNewswireInterim Report - January-June 2022

22.07.22GlobeNewswireKarolinska Developments portfolio company Promimic and Danco Medical form a joint venture for the US-market

04.07.22GlobeNewswireKarolinska Development expands its portfolio following an investment in PharmNovo

Karolinska Development (B) News

Karolinska Development (B) News: auf dieser Seite finden Sie alle Karolinska Development (B) News und Nachrichten zur Karolinska Development (B) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Karolinska Development (B) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Karolinska Development (B) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.